Evidence map›Paper›PMID 29155621›Full record

ArticleRadiology2017

Science to Practice: Enhancing Photothermal Ablation of Colorectal Liver Metastases with Targeted Hybrid Nanoparticles.

Xiaoming Yang

Abstract readComment
In one paragraph

Article in Radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Xiaoming YangImage-Guided Bio-Molecular Interventions Research and Division of Interventional Radiology, Department of Radiology University of Washington School of Medicine 815 Mercer St, Room S470, Campus Box 358056 Seattle, WA 98109.

Funding

Intrabiliary MR/RF-enhanced chemotherapy of malignant biliary obstructionsR01EB012467 · NIBIB · UNIVERSITY OF WASHINGTON · PI YANG, XIAOMING · 2011 to 2015
$5.6M
Development of a 3D multi-modal perfusion-thermal electrode systemR01EB028095 · NIBIB · UNIVERSITY OF WASHINGTON · PI YANG, XIAOMING · 2019 to 2022
$2.4M
NIBIB NIH HHS R01 EB012467NIBIB NIH HHS R01 EB028095
6 · The paper itself

Abstract

Image-guided percutaneous thermal ablation has been one of the principal tools in management of unresectable liver malignancies, including colorectal liver metastases (CRLM) ( 1 ). Currently, however, this technique is suitable mainly for tumors less than 4-5 cm in diameter and also results in incomplete ablation at tumor margins ( 2 ). To solve these problems, efforts have been made to combine thermal ablation with other treatment options, such as systemic and intra-arterial administration of therapeutics ( 3 - 5 ). In this issue of Radiology, White et al ( 6 ) introduced their work on development of an alternative approach by using biofunctionalized hybrid magnetic gold nanoparticles (HNPs) as catalysts for photothermal ablation of CRLM. They found that (a) the targeted (anti-MG1) HNPs are noncytotoxic and have greater than 20% intratumoral accumulation and (b) systemic administration of anti-MG1 HNPs can enlarge a tumor's necrotic zone with photothermal ablation. The results of this study establish the proof of the concept that targeted HNPs can enhance the therapeutic effect of photothermal ablation, which presents an exciting strategy for complete removal of CRLM by integrating two rapidly advancing scientific fields-interventional radiology and nanotechnology.

Indexed as

AnimalsBiological Science DisciplinesColorectal NeoplasmsHumansHyperthermia, InducedLiver NeoplasmsMolecular Targeted TherapyNanoconjugatesPhototherapyTranslational Research, BiomedicalTreatment OutcomeNanoconjugates

Identifiers

PMID29155621
PMCPMC5708282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.